Answers are grounded in this paper and cite their sources.
Phase I trial demonstrates the initiation of the ChAdOx1 BDBV candidate in human volunteers, suggesting enhanced readiness for future Bundibugyo virus outbreaks.
On July 24, 2026, Oxford reported administering ChAdOx1 BDBV to the first participant in BD-Ebov, the first Phase I trial of a vaccine designed specifically against Bundibugyo virus.
No takes yet. Share an insight, caveat, or question.
Mohamed et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: